For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 3,472 | |||
| Selling, general and administrative (including 432,000 and 230,000 of stock compensation during the years ended december 31, 2025 and 2024, respectively) | 8,950 | |||
| Loss from operations | -12,422 | |||
| Interest income | 123 | |||
| Interest expense | 127 | |||
| Loss on initial recognition of greenshoe rights liability | 28,736 | |||
| Change in fair value of greenshoe rights liability | -11,413 | |||
| Change in fair value of warrant liability | -241 | |||
| Gain on settlement of vendor payable | 998 | |||
| Other | 156 | |||
| Total other income (expense), net | -15,932 | |||
| Net loss | -28,354 | |||
| Dividend on series l preferred stock | -320 | |||
| Deemed dividend | -5,775 | |||
| Net loss attributable to common stockholders | -34,449 | |||
| Basic EPS | -6.68 | |||
| Diluted EPS | -6.68 | |||
| Basic Average Shares | 5,513,255 | |||
| Diluted Average Shares | 5,513,255 | |||
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)